Award
NIH Reporter #1R43CA302053-01
A novel multi-analyte algorithmic assay diagnostic for hepatocellular carcinoma (HCC)
Recipient
ImCare Biotech
Award Amount
$364,763.00
Ceiling
$364,763.00
Awarded
June 20, 2025
Identifier
1R43CA302053-01
Award to ImCare Biotech to develop and validate Seravue AI, a blood test using AI for early detection of hepatocellular carcinoma, funded by the National Cancer Institute.
Description
ImCare Biotech is seeking to develop and validate Seravue AI, a novel multi-analyte algorithmic assay for early detection of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. HCC is a leading cause of cancer-related deaths worldwide, with poor prognosis when detected late. Early detection significantly improves survival rates, but current surveillance methods have limitations in accuracy and accessibility, especially with imaging. Seravue AI addresses this critical need by combining ImCare Biotech's proprietary LC-SPIK biomarker with established markers AFP and DCP, integrated through an advanced AI algorithm, and only requires a simple blood sample for highly sensitive and specific HCC detection.